Identification of aurintricarboxylic acid as a potent allosteric antagonist of P2X1 and P2X3 receptors.


Journal

Neuropharmacology
ISSN: 1873-7064
Titre abrégé: Neuropharmacology
Pays: England
ID NLM: 0236217

Informations de publication

Date de publication:
01 11 2019
Historique:
received: 03 07 2019
revised: 14 08 2019
accepted: 23 08 2019
pubmed: 29 8 2019
medline: 21 7 2020
entrez: 29 8 2019
Statut: ppublish

Résumé

The homotrimeric P2X3 receptor, one of the seven members of the ATP-gated P2X receptor family, plays a crucial role in sensory neurotransmission. P2X3 receptor antagonists have been identified as promising drugs to treat chronic cough and are suggested to offer pain relief in chronic pain such as neuropathic pain. Here, we analysed whether compounds affect P2X3 receptor activity by high-throughput screening of the Spectrum Collection of 2000 approved drugs, natural products and bioactive substances. We identified aurintricarboxylic acid (ATA) as a nanomolar-potency antagonist of P2X3 receptor-mediated responses. Two-electrode voltage clamp electrophysiology-based concentration-response analysis and selectivity profiling revealed that ATA strongly inhibits the rP2X1 and rP2X3 receptors (with IC

Identifiants

pubmed: 31461640
pii: S0028-3908(19)30308-9
doi: 10.1016/j.neuropharm.2019.107749
pii:
doi:

Substances chimiques

Purinergic P2X Receptor Antagonists 0
Receptors, Purinergic P2X1 0
Receptors, Purinergic P2X3 0
Aurintricarboxylic Acid 4431-00-9

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

107749

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Astrid S Obrecht (AS)

Molecular Pharmacology, RWTH Aachen University, 52074, Aachen, Germany.

Nicole Urban (N)

Rudolf-Boehm-Institut for Pharmacology and Toxicology, University of Leipzig, 04107, Leipzig, Germany.

Michael Schaefer (M)

Rudolf-Boehm-Institut for Pharmacology and Toxicology, University of Leipzig, 04107, Leipzig, Germany.

Anni Röse (A)

Molecular Pharmacology, RWTH Aachen University, 52074, Aachen, Germany.

Achim Kless (A)

Grünenthal Innovation, Department of Translational Science and Intelligence, Grünenthal GmbH, 52078, Aachen, Germany.

Jannis E Meents (JE)

Institute of Physiology, RWTH Aachen University, 52074, Aachen, Germany.

Angelika Lampert (A)

Institute of Physiology, RWTH Aachen University, 52074, Aachen, Germany.

Aliaa Abdelrahman (A)

PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, 53121, Bonn, Germany.

Christa E Müller (CE)

PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, 53121, Bonn, Germany.

Günther Schmalzing (G)

Molecular Pharmacology, RWTH Aachen University, 52074, Aachen, Germany.

Ralf Hausmann (R)

Molecular Pharmacology, RWTH Aachen University, 52074, Aachen, Germany. Electronic address: rhausmann@ukaachen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH